Peptide fragments of human serum albumin as novel renal targeting carriers

Yuan, Zhixiang; He, Xia-kai; Wu, Xiaojuan; Gao, Yuan; Fan, M.-Y.; Song, Lian-qiang; Xu, Chunping

doi:10.1016/j.ijpharm.2013.10.041

Cited by 21 publications

(22 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5B). This finding is again in agreement with the renal retention profile of PF-A 299-585 obtained in our previous study [12]. Taken together, it is apparent that PF-A 299-585 has merited potential as a targeting ligand for the renal accumulation of active therapeutics.…”

Section: In Vivo Studysupporting

confidence: 91%

“…Succinic acid, fluorescein isothiocyanate (FITC) and bovine serum albumin (BSA) were obtained from Sigma-Aldrich Co. Ltd. (Gillingham, UK). PF-A 299-585 was prepared according to methods reported in our previous paper [12]. MDCK cells were from the American Type Culture Collection (VA, USA).…”

Section: Materials and Animalsmentioning

confidence: 99%

“…Untreated MDCK cells served as a negative control. In vivo fluorescence imaging of FITC-TPS-PF-A 299-585 was carried out according to the previous method [12]. Kunming mice were injected through the caudal vein with FITC-TPS-PF-A 299-585 dissolved in normal saline (1 mg/ml) at a dose of 10 mg/kg.…”

Section: Cellular Uptakementioning

confidence: 99%

“…Peptide fragments (PFs) of the human serum albumin have previously been shown by our laboratory to accumulate in the kidney after parenteral administration, which may allow them to be developed into renal targeting ligands [12]. Among the peptide fragments examined, PF-A 299-585 showed the greatest promise, with about 40% of the injected doses accumulating in the kidneys at 1 h post-injection, presumably via the endocytic pathway mediated by the cubilin/megalin receptor on the apical membrane of proximal tubular cells that is known to transport low molecular weight proteins [13].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Renal targeted delivery of triptolide by conjugation to the fragment peptide of human serum albumin

Yuan

et al. 2015

European Journal of Pharmaceutics and Biopharmaceutics

Self Cite

View full text Add to dashboard Cite

Section: In Vivo Studysupporting

confidence: 91%

Section: Materials and Animalsmentioning

confidence: 99%

Section: Cellular Uptakementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Renal targeted delivery of triptolide by conjugation to the fragment peptide of human serum albumin

Yuan

et al. 2015

European Journal of Pharmaceutics and Biopharmaceutics

Self Cite

View full text Add to dashboard Cite

“…10,11 These carriers have been shown to achieve effective targeted delivery of prednisolone or triptolide (TP) to the renal tubules. However, they may not be effective carriers of drugs required for the treatment of inflammatory and pathogenic glomeruli diseases.…”

mentioning

confidence: 99%

Renal-targeted delivery of triptolide by entrapment in pegylated TRX-20-modified liposomes

Yuan

Jia

Lim

et al. 2017

IJN

Self Cite

View full text Add to dashboard Cite

Previously, 3,5-dipentadecyloxybenzamidine hydrochloride (TRX-20)-modified liposomes were reported to specifically target mesangial cells (MCs) in glomeruli. To further gain a better understanding of the characteristics and potential application for glomerular diseases of TRX-20-modified liposomes, we synthesized TRX-20 and prepared TRX-20-modified liposomes (TRX-LPs) with different molar ratios – 6% (6%-TRX-LP), 11% (11%-TRX-LP), and 14% (14%-TRX-LP) – of TRX-20 to total lipid in the present study. All TRX-LPs exhibited concentration-dependent toxicity against the MCs at a lipid concentration ranging from 0.01 to 1.0 mg/mL with IC 50 values of 3.45, 1.13, and 0.55 mg/mL, respectively. Comparison of the cell viability of TRX-LPs indicated that high levels of TRX-20 caused severe cell mortality, with 11%-TRX-LP showing the higher cytoplasmic accumulation in the MCs. Triptolide (TP) as a model drug was first loaded into 11%-TRX-LP and the liposomes were further modified with PEG 5000 (PEG-TRX-TP-LP) in an attempt to prolong their circulation in blood and enhance TP-mediated immune suppression. Due to specific binding to MCs, PEG-TRX-TP-LP undoubtedly showed better anti-inflammatory action in vitro, evidenced by the inhibition of release of nitric oxide (NO) and tumor necrosis factor-α from lipopolysaccharide-stimulated MCs, compared with free TP at the same dose. In vivo, the PEG-TRX-TP-LP effectively attenuated the symptoms of membranous nephropathic (MN) rats and improved biochemical markers including proteinuria, serum cholesterol, and albumin. Therefore, it can be concluded that the TRX-modified liposome is an effective platform to target the delivery of TP to glomeruli for the treatment of MN.

show abstract

Self‐Assembling P38 Peptide Inhibitor Nanoparticles Ameliorate the Transition from Acute to Chronic Kidney Disease by Suppressing Ferroptosis

Xin,

Gong,

Chen

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Accumulating evidence highlights p38 as a crucial factor highly activated during the process of acute kidney injury (AKI), but the application of p38 inhibitor in AKI was quite limited due to the low efficiency and poor kidney‐targeting ability. Herein, a novel self‐assembling peptide nanoparticle with specific p38‐inhibiting activity was constructed, which linked mitogen‐activated protein kinase kinase 3b (MKK3b), the functional domain of p38, with the cell‐penetrating TAT sequence, ultimately self‐assembling into TAT‐MKK3b nanoparticles (TMNPs) through tyrosinase oxidation. Subsequent in vitro and in vivo studies demonstrated that TMNPs preferably accumulated in the renal tubular epithelial cells (RTECs) through forming protein coronas by binding to albumin, and strongly improved the reduced renal function of ischemia‐reperfusion injury (IRI)‐induced AKI and its transition to chronic kidney disease (CKD). Mechanically, TMNPs inhibited ferroptosis via its solute carrier family 7 member 11 (SLC7A11)/glutathione peroxidase 4 (GPX4) axis‐inducing capacity and synergistic potent antioxidant property in AKI. Our findings indicated that the multifunctional TMNPs exhibited renal targeting, ROS‐scavenging and ferroptosis‐mitigating capabilities, which may serve as a promising therapeutic agent for the treatment of AKI and its progression to CKD.This article is protected by copyright. All rights reserved

show abstract

Peptide fragments of human serum albumin as novel renal targeting carriers

Cited by 21 publications

References 34 publications

Renal targeted delivery of triptolide by conjugation to the fragment peptide of human serum albumin

Renal targeted delivery of triptolide by conjugation to the fragment peptide of human serum albumin

Renal-targeted delivery of triptolide by entrapment in pegylated TRX-20-modified liposomes

Self‐Assembling P38 Peptide Inhibitor Nanoparticles Ameliorate the Transition from Acute to Chronic Kidney Disease by Suppressing Ferroptosis

Contact Info

Product

Resources

About